SPECIALITY pharmaceutical company iX Biopharma on Wednesday announced it has installed new freeze-dry equipment that will allow it to expand its current wafer production capacity for its WaferiX sublingual wafers by up to six times. The company is on track to produce its first commercial batch of wafers in July 2021, it said in its bourse filing.
Read More
